Bone Biologics Corp Stock Alpha and Beta Analysis
| BBLGW Stock | USD 20.20 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bone Biologics Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bone Biologics over a specified time horizon. Remember, high Bone Biologics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bone Biologics' market risk premium analysis include:
Beta 5.82 | Alpha 4.55 | Risk 18.78 | Sharpe Ratio 0.0522 | Expected Return 0.98 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Bone |
Bone Biologics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bone Biologics market risk premium is the additional return an investor will receive from holding Bone Biologics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bone Biologics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bone Biologics' performance over market.| α | 4.55 | β | 5.82 |
Bone Biologics Fundamentals Vs Peers
Comparing Bone Biologics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bone Biologics' direct or indirect competition across all of the common fundamentals between Bone Biologics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bone Biologics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bone Biologics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bone Biologics to competition |
| Fundamentals | Bone Biologics | Peer Average |
| Return On Equity | -1.29 | -0.31 |
| Return On Asset | -0.69 | -0.14 |
| Number Of Shares Shorted | 197 | 4.71 M |
| EBITDA | (4.22 M) | 3.9 B |
| Net Income | (4.11 M) | 570.98 M |
| Cash And Equivalents | 4.44 K | 2.7 B |
| Total Debt | 377.71 K | 5.32 B |
Bone Biologics Opportunities
Bone Biologics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Trading Signals - Stock Traders Daily | 05/16/2024 |
2 | First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion | 06/20/2024 |
3 | Acquisition by Heshmatpour Amir F of 200000 shares of Bone Biologics subject to Rule 16b-3 | 07/24/2024 |
4 | Acquisition by Hankey Bret of 1063830 shares of Bone Biologics subject to Rule 16b-3 | 10/30/2024 |
5 | Acquisition by Booth John J of 26780 shares of Bone Biologics at 2.05 subject to Rule 16b-3 | 11/12/2024 |
6 | Acquisition by Hankey Don of 1063830 shares of Bone Biologics subject to Rule 16b-3 | 11/27/2024 |
7 | Accuray Stock Surges Amidst Market Activity - GuruFocus.com | 02/05/2025 |
8 | Acquisition by Musculoskeletal Transplant Foundation, Inc. of 731707 shares of Bone Biologics at 2.05 subject to Rule 16b-3 | 02/18/2025 |
About Bone Biologics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bone or other stocks. Alpha measures the amount that position in Bone Biologics Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.001341 | 0.001274 | Days Of Inventory On Hand | 368.2 | 327.29 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bone Biologics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bone Biologics' short interest history, or implied volatility extrapolated from Bone Biologics options trading.
Build Portfolio with Bone Biologics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.